Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D02027 (
Tranilast
)
205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of
Tranilast
[N-(3,4-dimethoxycinnamoyl) anthranilic acid] on the synthesis of prostaglandin D2 (PGD2) by homogenates of rat peritoneal mast cells was investigated. The major cyclooxygenase product formed by mast cell homogenates was PGD2, smaller quantities of PGE2 and PGF2 alpha were also formed.
Tranilast
suppressed the production of PGD2 in a dose-dependent manner with an IC50 of 0.1 mM. This suppression was due to inhibition of PGD synthetase, but not cyclooxygenase, since the formation of PGE2 and PGF2 alpha were unchanged at a 0.1 mM concentration. In addition, the glutathione-dependent conversion of [14C]PGH2 to PGD2 by PGD synthetase (PGH-D isomerase,
EC 5.3.99.2
) was inhibited by
Tranilast
, with 50% inhibition achieved at 0.08 mM in broken cell preparations of rat peritoneal mast cells.
Tranilast
also inhibited purified rat spleen and brain PGD synthetases. Furthermore,
Tranilast
prevented the PGD2 generation from intact mast cells stimulated by the calcium ionophore A23187. These results suggest that
Tranilast
exerts some of its therapeutic effects by prevention of PGD2 generation in mast cells and some other tissues.
...
PMID:Inhibitory effect of tranilast on prostaglandin D synthetase. 247 13